In conclusion, no new safety and efficacy concerns were observed in this interim analysis of PMS in Japanese patients with unresectable melanoma with BRAF mutation who received dabrafenib and trametinib in the real-world clinical setting. This evidence concerns the gene BRAF and melanoma.